GT Biopharma Explores A New Combination Approach For Pancreatic Cancer

GT Biopharma (GTBP) received FDA clearance for GTB-5550, a B7-H3-targeted therapy, to begin Phase 1 trials in multiple myeloma. The trial, contingent on grant funding, will evaluate safety, tolerability, and anti-tumor activity. The company has $11M in cash, expected to last until Q3 2027. GTBP stock is down 22.96% to $8.96.

GT Biopharma, a clinical-stage immuno-oncology company using its TriKE natural killer cell engager platform, said AI tools rolled out internally have improved discovery and drug engineering productivity. The company plans to advance lead programs GTB-3650 and GTB-5550 through Phase 1 studies this year and use AI for candidate selection, molecular design, and structural modeling. Shares were up 0.38% to $0.48 premarket, per Benzinga Pro.

Anthropic agreed to pay $3.4 billion for 1.7 gigawatts of Caterpillar gas generators, originally ordered by OnePWR Solutions. The deal is roughly the size of Caterpillar's Q3 power generation sales. Anthropic, heading for a large IPO, has significant cash reserves. Caterpillar's backlog includes the order, improving payment certainty.

Cantor Fitzgerald initiated coverage of Ross Stores (ROST) with an Overweight rating, expecting comparable store sales and EPS above consensus levels in upcoming quarters, according to analyst John Kernan.

JP Morgan reaffirmed its Overweight rating for McKesson and increased its price target to $1255 from $1042, citing a 18.5% potential upside from the Nov 9 close of $1059.37. Recent analyst price targets for McKesson range from $965 to $1250.

CNBC Investing Club discussed market trends, downgrading Nvidia to a hold due to uncertainty around CEO Jensen Huang's investigation. Jim Cramer noted oil price drops may ease inflation, potentially limiting Fed rate hikes. He also expressed interest in adding to Constellation Brands position but awaits a stock decline.